Patents by Inventor Marc Doubleday
Marc Doubleday has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210230663Abstract: In some embodiments, the invention provides methods for detecting the reversal an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of an ecarin reagent to obtain a control ecarin clotting measurement; subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control Factor Xa clotting measurement; subjecting a sample of a blood component from a patient suspected to contain a reversal agent to a clotting assay in the presence of the ecarin reagent to obtain a patient ecarin clotting measurement; subjecting a sample of a blood component from the patient suspected to contain the reversal agent to a clotting assay in the presence of the Factor Xa reagent to obtain a patient Factor Xa clotting measurement; and comparing the control ecarin clotting measurType: ApplicationFiled: February 23, 2021Publication date: July 29, 2021Inventors: Fowzia S. Zaman, Marc Doubleday
-
Patent number: 10954549Abstract: In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent.Type: GrantFiled: November 5, 2019Date of Patent: March 23, 2021Assignee: Haemonetics CorporationInventors: Fowzia S. Zaman, Marc Doubleday
-
Publication number: 20200063184Abstract: In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent.Type: ApplicationFiled: November 5, 2019Publication date: February 27, 2020Inventors: Fowzia S. Zaman, Marc Doubleday
-
Patent number: 10501773Abstract: In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent.Type: GrantFiled: July 30, 2015Date of Patent: December 10, 2019Assignee: Haemonetics CorporationInventors: Fowzia S. Zaman, Marc Doubleday
-
Publication number: 20170355961Abstract: Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes.Type: ApplicationFiled: May 23, 2017Publication date: December 14, 2017Inventors: Jose Oberholzer, Marc Doubleday
-
Patent number: 9657271Abstract: Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes.Type: GrantFiled: January 31, 2013Date of Patent: May 23, 2017Assignees: The Board of Trustees of the University of Illinois, Hemoglobin Oxygen Therapeutics LLCInventors: Jose Oberholzer, Marc Doubleday
-
Publication number: 20160032355Abstract: In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent.Type: ApplicationFiled: July 30, 2015Publication date: February 4, 2016Inventors: Fowzia S. Zaman, Marc Doubleday
-
Publication number: 20110200981Abstract: Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes.Type: ApplicationFiled: March 7, 2011Publication date: August 18, 2011Applicant: OPK Biotech LLCInventor: Marc Doubleday
-
Patent number: 7435795Abstract: A hemoglobin solution packaged in a flexible oxygen-impermeable container system. The container system includes a multi-layer film having at least a product contact layer, an oxygen and moisture barrier layer and an exterior layer. The flexible container system further includes an interface port for filling the flexible container with the hemoglobin solution and delivering the hemoglobin solution. The hemoglobin solution comprises a substantially stroma and tetramer free, cross linked, pyridoxylated hemoglobin solution including preservatives such as ascorbic acid, glycine and dextrose.Type: GrantFiled: February 23, 2007Date of Patent: October 14, 2008Assignee: Northfield Laboratories, Inc.Inventors: Robert McGinnis, Gabriel Chavez, Marc Doubleday, Richard DeWoskin, Anthony Avella
-
Patent number: 7411044Abstract: A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution.Type: GrantFiled: August 24, 2006Date of Patent: August 12, 2008Assignee: Northfield Laboratories, Inc.Inventors: Anthony Avella, Richard DeWoskin, Marc Doubleday
-
Publication number: 20080108555Abstract: A process is disclosed for the preparation of an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.Type: ApplicationFiled: January 10, 2008Publication date: May 8, 2008Inventors: Richard DeWoskin, Marc Doubleday
-
Patent number: 7291592Abstract: Methods for treating a mammal suffering from massive blood loss comprising administering to the mammal a polymerized hemoglobin solution.Type: GrantFiled: October 3, 2003Date of Patent: November 6, 2007Assignee: Northfield Laboratories, Inc.Inventors: Steven Gould, Richard DeWoskin, Marc Doubleday, George Hides
-
Publication number: 20070196810Abstract: Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes.Type: ApplicationFiled: January 24, 2007Publication date: August 23, 2007Inventor: Marc Doubleday
-
Publication number: 20070173435Abstract: A hemoglobin solution packaged in a flexible oxygen-impermeable container system. The container system includes a multi-layer film having at least a product contact layer, an oxygen and moisture barrier layer and an exterior layer. The flexible container system further includes an interface port for filling the flexible container with the hemoglobin solution and delivering the hemoglobin solution. The hemoglobin solution comprises a substantially stroma and tetramer free, cross linked, pyridoxylated hemoglobin solution including preservatives such as ascorbic acid, glycine and dextrose.Type: ApplicationFiled: February 23, 2007Publication date: July 26, 2007Applicant: Northfield Laboratories, Inc.Inventors: Robert McGinnis, Gabriel Chavez, Marc Doubleday, Richard DeWoskin, Anthony Avella
-
Patent number: 7202341Abstract: A hemoglobin solution packaged in a flexible oxygen-impermeable container system. The container system includes a multi-layer film having at least a product contact layer, an oxygen and moisture barrier layer and an exterior layer. The flexible container system further includes an interface port for filling the flexible container with the hemoglobin solution and delivering the hemoglobin solution. The hemoglobin solution comprises a substantially stroma and tetramer free, cross linked, pyridoxylated hemoglobin solution including preservatives such as ascorbic acid, glycine and dextrose.Type: GrantFiled: September 21, 2005Date of Patent: April 10, 2007Assignee: Northfield Laboratories, Inc.Inventors: Robert McGinnis, Gabriel Chavez, Marc Doubleday, Richard DeWoskin, Anthony Avella
-
Publication number: 20060287222Abstract: A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution.Type: ApplicationFiled: August 24, 2006Publication date: December 21, 2006Applicant: Northfield Laboratories, Inc.Inventors: Anthony Avella, Richard DeWoskin, Marc Doubleday
-
Patent number: 7135553Abstract: A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution.Type: GrantFiled: January 29, 2004Date of Patent: November 14, 2006Assignee: Northfield Laboratories, Inc.Inventors: Anthony Avella, Richard DeWoskin, Marc Doubleday
-
Publication number: 20060014671Abstract: A hemoglobin solution packaged in a flexible oxygen-impermeable container system. The container system includes a multi-layer film having at least a product contact layer, an oxygen and moisture barrier layer and an exterior layer. The flexible container system further includes an interface port for filling the flexible container with the hemoglobin solution and delivering the hemoglobin solution. The hemoglobin solution comprises a substantially stroma and tetramer free, cross linked, pyridoxylated hemoglobin solution including preservatives such as ascorbic acid, glycine and dextrose.Type: ApplicationFiled: September 21, 2005Publication date: January 19, 2006Applicant: Northfield Laboratories, Inc.Inventors: Robert McGinnis, Gabriel Chavez, Marc Doubleday, Richard DeWoskin, Anthony Avella
-
Publication number: 20050065067Abstract: A process is disclosed for the preparation of an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.Type: ApplicationFiled: November 19, 2004Publication date: March 24, 2005Inventors: Richard DeWoskin, Marc Doubleday
-
Publication number: 20040186047Abstract: A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution.Type: ApplicationFiled: January 29, 2004Publication date: September 23, 2004Applicant: Northfield LaboratoriesInventors: Anthony Avella, Richard DeWoskin, Marc Doubleday